SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Democratic gains in the midterms are driving intense debate over the market outlook, with traders concerned about possible data-center and AI regulation, tax changes, and political uncertainty. Others argue the result is already priced in and that divided government could limit policy changes, pointing to a sharp rebound in futures after the initial selloff.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Projected Democratic control of Congress is the dominant catalyst, with traders viewing the midterm losses as a major political setback for Trump and many expressing bearish sentiment on DJT amid speculation about investigations and a weakened agenda. Some argue congressional gridlock could limit policy changes, but the conversation is largely focused on the elections implications for Trump and the company.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Democratic gains in Congress are driving debate over QQQ: some traders fear tighter AI and data-center rules could weigh on the tech-heavy Nasdaq, while others see gridlock and reduced uncertainty as supportive. The community is split after a sharp selloff and rebound, with dip-buyers calling it a relief move and bears warning of further tech weakness.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Democratic election gains, including in Texas, are driving concern that SpaceX could face greater scrutiny of Musks government ties, contracts, data-center plans, and a possible Tesla merger. Traders disagree on the impact: some expect political headwinds, while others argue the projects can proceed and view the weakness as a buying opportunity.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Traders are debating a volatile post-election reaction, with speculation that Democratic gains could lead to data-center restrictions and slow AI spending weighing on MU and other chip stocks. Bulls counter that the risk is overstated and point to strong AI-related memory demand, rising memory prices, and upbeat AMD results as reasons for optimism.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Apples warning that memory prices are rising and expected to keep climbing has renewed bullish interest in SanDisk and other memory stocks, with traders viewing it as evidence of tight supply and pricing strength. The rebound is contested, as many remain wary of the sectors sharp recent swings and question whether AI-related demand can offset memorys cyclical risks.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros blowout quarterly results and higher full-year outlook, driven by strong AI-server demand, are the main focus. Traders are upbeat about growth and the new guidance but debate whether thin margins and lingering confidence concerns justify the muted, volatile share reaction.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL swung sharply as Democratic election gains sparked fears of tighter data-center rules and slower AI infrastructure spending, weighing on semiconductor stocks. Traders debated whether the selloff was an overreaction, while chip shares rebounded with election uncertainty easing and AMD and SMCI results supporting sentiment.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is drawing attention over traders reaction to perceived Democratic gains in the elections and Elon Musks political involvement. Many fear added scrutiny of Musks companies, reduced government support, and complications for a possible SpaceX merger, while some argue EV policies could benefit Tesla or view the selloff as a buying opportunity.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles stock-and-bond financing for its AI data-center expansion is driving debate over dilution, borrowing costs and whether future cloud revenue will generate enough cash to justify the spending. Some traders view the completed fundraising and share-price rebound as easing the overhang, while others remain concerned about debt and further downside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immunovant Q1 2027 Earnings Call: Complete Transcript

Immunovant (NASDAQ:IMVT) held its first-quarter earnings conference call on Thursday. Below is the complete transcript from the call.
Benzinga APIs provide real-time access to earnings call transcripts and financialread more...

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law FirmPR NewswireNEW YORK, Oct. 12, 2026NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain...

IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Immunovant, Inc. (Immunovant or the Company) (NASDAQ: IMVT) for violations of the securities laws.INVESTIGATION DETAILS: The investigation focuses...

IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class

Equity

Immunovant is developing IMVT-1402 in an ongoing mid-stage study in Sjögren’s disease, which works the same way as Argenx’s efgartigimod.


Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)

Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT) Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)PR NewswireNEW YORK, Sept. 25, 2026 Immunovant stock fell roughly 6% to a...

IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down

Immunovant's IMVT-1402 misses its primary CLE goal, prompting the company to halt the program despite positive trends and a favorable safety profile.

Immunovant Ends Autoimmune Skin Disorder Program

Immunovant halts IMVT-1402 CLE trial after missing primary endpoints, driving IMVT and Roivant shares down in premarket trading.read more...

Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows

Immunovant is discontinuing development of IMVT-1402 in cutaneous lupus but will continue to develop the therapy for several other autoimmune diseases.


Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm PR Newswire NEW YORK, Aug. 19, 2026 NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether...

Immunovant (IMVT) Q1 2027 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It develops a novel, fully human monoclonal antibody, IMVT-1401, which selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded on July 6, 2018 and is headquartered in Durham, NC.

Immunovant Inc

Bearish Sentiment

<ul class="summary-bullets"><li>IMVT-1402 missed its main goal in a cutaneous lupus study in September, and that program was dropped.</li><li>H.C. Wainwright termed Argenx’s trial halt in Sjögren’s a “surprising setback.”</li><li>Wainwright said it is now more cautious about what the failure implies for Immunovant’s mid-stage study.</li></ul><p>Shares of Immunovant (IMVT) sold off Thursday as traders treated Argenx’s (ARGX) failed late-stage Sjögren’s trial as a warning for its own experimental drug for the autoimmune disorder.</p><p>Immunovant (IMVT) fell about 6% to $30.06 in morning trading. Its parent Roivant (ROIV) was also weaker, trading down roughly 2%.</p><h2 class="st-heading-2">Why Did IMVT, ROIV Fall On Rival Trial?</h2><p>Immunovant is developing IMVT-1402 in an ongoing mid-stage study in Sjögren’s disease. Argenx’s efgartigimod works the same way: it lowers circulating IgG antibodies that can drive autoimmune disease.</p><p>A late-stage failure for a closely related drug raises the odds that simply reducing IgG may not be enough in Sjögren’s. The move also follows Immunovant’s late-September setback, when IMVT-1402 missed its main goal in a cutaneous lupus study, and that program was dropped.</p><p>Roivant is the majority owner of Immunovant, and IMVT-1402 is central to the group’s autoimmune story.</p><h2 class="st-heading-2">ARGX’s Failed Trial</h2><p>Argenx has stopped its late-stage UNITY study of weekly subcutaneous efgartigimod in adults with moderate-to-severe Sjögren’s disease. An independent monitoring committee, after an interim look, said the trial was unlikely to meet its main goal: a reduction in systemic disease activity at week 48, the company said. Safety matched the drug’s known profile, with no new signals.</p><p>Sjögren’s, which causes dry eyes, dry mouth, fatigue and joint pain, still has no approved targeted therapy and is unusually varied from patient to patient, which makes trials hard to win.</p><p>Argenx’s U.S. shares were down about 14% to $797.69. The drug is already approved as Vyvgart for the treatment of generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP). The failed trial removes the Sjögren’s path for Vyvgart.</p><h2 class="st-heading-2">Analyst Weighs In On ARGX’s Failed Trial</h2><p>H.C. Wainwright analyst Douglas Tsao called it a good-news, bad-news day for Argenx. On the positive side, the analyst said a 126-patient mid-stage study of FB102 in celiac disease met its primary endpoint. Argenx acquired FB102 through its $2.2 billion acquisition of Forte Biosciences. The firm sees that result as real validation of Argenx’s Forte deal and a clear step toward a late-stage study.</p><p>The UNITY stop, by contrast, was a “surprising setback,” the firm said. Wainwright said it is now more cautious about what the failure implies for Immunovant’s mid-stage Sjögren’s study of IMVT-1402. It kept a ‘Buy’ on Argenx and a $1,202 price target.</p><h2 class="st-heading-2">How Did IMVT, ROIV, ARGX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around IMVT and ROIV was in 'neutral' and 'bearish' territory, respectively.</p><p>Sentiment around ARGX, however, jumped from 'bearish' to 'bullish' territory.</p><p><a class="mention" data-mention="$IMVT" data-symbol-id="IMVT" href="https://stocktwits.com/symbol/IMVT" target="_blank">IMVT stock</a> has gained 19% this year, while ROIV has gained 55%. ARGX, however, has lost 4%.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/trump-reportedly-bought-up-to-25-m-in-meta-stock-the-largest-reported-purchase-among-517-transactions/cZDUoxfRBNw">Trump Reportedly Bought Up To $25M In Meta Stock, The Largest Reported Purchase Among 517 Transactions</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

Immunovant is developing IMVT-1402 in an ongoing mid-stage study in Sjögren’s disease, which works the same way as Argenx’s efgartigimod.

Current Price	$29.04
Prev Close	$28.41
Open	$28.70
Dividend Yield	0.00%
50-Day Moving Average	$33.95
Beta	1.24
Avg. Volume	1.38M
PE Ratio	-10.34

52-Week High	$45.42
52-Week Low	$21.43
Market Capitalization	$5.87B
EPS (Annual)	-$2.77
Price to Book	8.15
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

IMVT Fundamentals